Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Plus Dalpicilib in HPV Negative, PD-1 Resistant Recurrent/Metastatic HNSCC
NCT05721443Phase 2Completed
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Dec 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Objective Response Rate at 12 months. Started Dec 2022; status: completed.
02
Drugs
dalpiciclib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05721443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05721443.